USA - NASDAQ:CADL - US1374041093 - Common Stock
The current stock price of CADL is 5.4 USD. In the past month the price decreased by -2.53%. In the past year, price decreased by -3.57%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. The company is headquartered in Needham, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2021-07-27. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
CANDEL THERAPEUTICS INC
117 Kendrick Street,, Suite 450
Needham MASSACHUSETTS US
CEO: Paul Peter Tak
Employees: 38
Phone: 16179165445
Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. The company is headquartered in Needham, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2021-07-27. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
The current stock price of CADL is 5.4 USD. The price increased by 1.69% in the last trading session.
CADL does not pay a dividend.
CADL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
CANDEL THERAPEUTICS INC (CADL) operates in the Health Care sector and the Biotechnology industry.
CANDEL THERAPEUTICS INC (CADL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.69).
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CADL.
ChartMill assigns a fundamental rating of 2 / 10 to CADL. The financial health of CADL is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months CADL reported a non-GAAP Earnings per Share(EPS) of -0.69. The EPS increased by 59.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.89% | ||
| ROE | -24.54% | ||
| Debt/Equity | 0.01 |
12 analysts have analysed CADL and the average price target is 20.06 USD. This implies a price increase of 271.48% is expected in the next year compared to the current price of 5.4.